For the Inventor, By the Inventor

Enter assignee name

Sandy, UT, United States of America

Signpath Pharma, Inc.

USPTO Granted Patents = 25

% Expired Patents = 4.0

CIPO Patents = 1

EPO Patents = 8

Forward Citations = 172

Loading Chart...

Loading Chart...

23 inventors (with patents filed for the assignee):

Lawrence Helson (19 out of 22 patents)

Annie Bouchard (10 out of 11 patents)

George M Shopp (5 out of 7 patents)

4. Daniel Emil Levy (4 out of 16 patents)

5. Saravanan Kappusamy (4 out of 4 patents)

6. John Kallikat Augustine (4 out of 4 patents)

7. Muhammed Majeed (3 out of 117 patents)

8. James D McChesney (3 out of 58 patents)

9. Peter P Sordillo (3 out of 3 patents)

10. Stephen W Burgess (2 out of 16 patents)

11. Razelle Kurzrock (2 out of 5 patents)

12. Lan Li (2 out of 5 patents)

13. Kapil Mehta (2 out of 16 patents)

14. Bharat Bhushan Aggarawal (2 out of 3 patents)

15. Walter Allen Shaw (2 out of 18 patents)

25 patents: Sort by Forward Citations

1. 12617809 - Cardioprotective lipid and method of use (2026-05-05),

2. 12551436 - Dosing regimens for treatment of proliferative disorders (2026-02-17),

3. 12004868 - Liposomal mitigation of drug-induced inhibition of the cardiac Ichannel (2024-06-11),

4. 11813356 - Dosing regimens for treatment of proliferative disorders (2023-11-14),

5. 11806401 - Prevention of drug-induced atrio-ventricular block (2023-11-07),

6. 11746119 - Cardiopathy-reducing phosphodiester lipids (2023-09-05),

7. 11643424 - Cardiopathy-reducing phosphodiester lipids (2023-05-09),

8. 10975111 - Cardiopathy-reducing phosphodiester lipids (2021-04-13),

9. 10739353 - Suppression of cytokine release and cytokine storm (2020-08-11),

10. 10617639 - Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current (2020-04-14),

11. 10532045 - Liposomal mitigation of drug-induced inhibition of the cardiac Ichannel (2020-01-14),

12. 10485768 - Treatment for glioblastoma (2019-11-26),

13. 10449193 - Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies (2019-10-22),

14. 10357458 - Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current (2019-07-23),

15. 10258691 - Protective effect of DMPC, DMPG, DMPC/DMPG, EGPG, LysoPG and LysoPC against drugs that cause channelopathies (2019-04-16),

Signpath Pharma, Inc. is a pharmaceutical company focused on developing innovative solutions for the healthcare industry. With a commitment to improving patient outcomes, we specialize in the research, development, and commercialization of novel therapeutics. Our dedicated team of scientists, researchers, and medical professionals work tirelessly to bring cutting-edge medications to market in order to address unmet medical needs. At Signpath Pharma, we are driven by our mission to make a positive impact on global health by delivering effective and accessible pharmaceutical products.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Signpath Pharma, Inc.

25 Patents

#4 in Sandy, UT

#157 in Utah

#13,320 in US

#25,614 in the World

Sandy, UT, United States of America

Signpath Pharma, Inc.

Forward Citations = 172

23 inventors:

Lawrence Helson (19 out of 22 patents)

Annie Bouchard (10 out of 11 patents)

George M Shopp (5 out of 7 patents)

4. Daniel Emil Levy (4 out of 16 patents)

5. Saravanan Kappusamy (4 out of 4 patents)

Please report any incorrect information to [email protected]

Loading…